Rhythm Pharmaceuticals Stock Cash Per Share
| RYTM Stock | USD 59.92 0.02 0.03% |
Rhythm Pharmaceuticals fundamentals help investors to digest information that contributes to Rhythm Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rhythm Stock. The fundamental analysis module provides a way to measure Rhythm Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rhythm Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 4.78 | 3.45 |
Rhythm | Cash Per Share |
Rhythm Pharmaceuticals Company Cash Per Share Analysis
Rhythm Pharmaceuticals' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Rhythm Pharmaceuticals Cash Per Share | 4.64 X |
Most of Rhythm Pharmaceuticals' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rhythm Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rhythm Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Rhythm Pharmaceuticals is extremely important. It helps to project a fair market value of Rhythm Stock properly, considering its historical fundamentals such as Cash Per Share. Since Rhythm Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rhythm Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rhythm Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Rhythm Cash Per Share Historical Pattern
Today, most investors in Rhythm Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Rhythm Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Rhythm Pharmaceuticals cash per share as a starting point in their analysis.
Rhythm Pharmaceuticals Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Rhythm Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Rhythm Pharmaceuticals has a Cash Per Share of 4.64 times. This is 6.67% higher than that of the Biotechnology sector and 7.16% higher than that of the Health Care industry. The cash per share for all United States stocks is 7.39% higher than that of the company.
Rhythm Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rhythm Pharmaceuticals' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rhythm Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rhythm Pharmaceuticals by comparing valuation metrics of similar companies.Rhythm Pharmaceuticals is currently under evaluation in cash per share category among its peers.
Rhythm Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rhythm Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rhythm Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rhythm Fundamentals
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.46 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 3.39 B | ||||
| Shares Outstanding | 61.46 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 99.48 % | ||||
| Number Of Shares Shorted | 8.36 M | ||||
| Price To Book | 328.47 X | ||||
| Price To Sales | 32.74 X | ||||
| Revenue | 77.43 M | ||||
| Gross Profit | 21.5 M | ||||
| EBITDA | (168.46 M) | ||||
| Net Income | (184.68 M) | ||||
| Cash And Equivalents | 235.6 M | ||||
| Cash Per Share | 4.64 X | ||||
| Total Debt | 1.26 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (136.16 M) | ||||
| Short Ratio | 27.30 X | ||||
| Earnings Per Share | (4.32) X | ||||
| Price To Earnings To Growth | 0.75 X | ||||
| Target Price | 70.27 | ||||
| Number Of Employees | 226 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 3.68 B | ||||
| Total Asset | 332.75 M | ||||
| Retained Earnings | (894.74 M) | ||||
| Working Capital | 253.06 M | ||||
| Net Asset | 332.75 M |
About Rhythm Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rhythm Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rhythm Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rhythm Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Rhythm Pharmaceuticals Piotroski F Score and Rhythm Pharmaceuticals Altman Z Score analysis. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.